Tenet Reports Strong Third Quarter 2024 Results; Raises 2024 Financial Outlook
Tenet Healthcare (NYSE: THC) reported strong Q3 2024 results with net income of $472 million ($4.89 per diluted share), including a $209 million after-tax gain from hospital divestitures. Consolidated Adjusted EBITDA reached $978 million, up 14.5% year-over-year. The company's Ambulatory Care segment showed impressive growth with Adjusted EBITDA of $439 million, increasing 18.6%. Based on strong performance, Tenet raised its FY 2024 Adjusted EBITDA outlook to $3.9-4.0 billion, a $50 million increase. The company demonstrated robust cash flow generation with $2.378 billion from operating activities for the first nine months of 2024.
Tenet Healthcare (NYSE: THC) ha riportato risultati solidi per il terzo trimestre del 2024, con un reddito netto di $472 milioni ($4,89 per azione diluita), inclusa una plusvalenza dopo le tasse di $209 milioni derivante dalla dismissione di ospedali. Il Consolidated Adjusted EBITDA ha raggiunto $978 milioni, in aumento del 14,5% rispetto all'anno precedente. Il segmento di Cure Ambulatoriali dell'azienda ha mostrato una crescita impressionante con un Adjusted EBITDA di $439 milioni, in aumento del 18,6%. Sulla base delle forti performance, Tenet ha aumentato la sua previsione di Adjusted EBITDA per l'anno fiscale 2024 a $3,9-4,0 miliardi, con un incremento di $50 milioni. L'azienda ha dimostrato una robusta generazione di flusso di cassa con $2,378 miliardi provenienti dalle attività operative nei primi nove mesi del 2024.
Tenet Healthcare (NYSE: THC) reportó resultados fuertes para el tercer trimestre de 2024 con un ingreso neto de $472 millones ($4.89 por acción diluida), incluyendo una ganancia después de impuestos de $209 millones por la desinversión de hospitales. El EBITDA Ajustado Consolidado alcanzó $978 millones, un aumento del 14.5% interanual. El segmento de Atención Ambulatoria de la compañía mostró un crecimiento impresionante con un EBITDA Ajustado de $439 millones, incrementándose en un 18.6%. Basado en un desempeño sólido, Tenet elevó su perspectiva de EBITDA Ajustado para el año fiscal 2024 a $3.9-4.0 mil millones, un aumento de $50 millones. La compañía demostró una generación de flujo de efectivo robusta con $2.378 mil millones provenientes de actividades operativas durante los primeros nueve meses de 2024.
테넷 헬스케어 (NYSE: THC)는 2024년 3분기 강력한 실적을 발표했으며, 순이익은 4억 7천2백만 달러($4.89 희석된 주당 순이익)입니다. 여기에는 병원 매각으로 인한 세후 2억 9백만 달러의 이익이 포함됩니다. 조정된 EBITDA는 9억 7천8백만 달러에 도달했으며, 전년 대비 14.5% 증가했습니다. 회사의 외래 진료 부문은 4억 3천9백만 달러의 조정된 EBITDA로 18.6% 증가하며 인상적인 성장을 보여주었습니다. 강력한 성과에 기반하여 테넷은 2024 회계연도의 조정된 EBITDA 전망을 39억에서 40억 달러로 상향 조정했으며, 이는 5천만 달러의 증가입니다. 회사는 2024년 첫 9개월 동안 운영 활동으로부터 23억 7천8백만 달러의 견고한 현금 흐름을 생성했습니다.
Tenet Healthcare (NYSE: THC) a annoncé de solides résultats pour le troisième trimestre 2024, avec un revenu net de 472 millions de dollars (4,89 dollars par action diluée), y compris un gain après impôts de 209 millions de dollars provenant de la cession d'hôpitaux. Le EBITDA Ajusté Consolidé a atteint 978 millions de dollars, en hausse de 14,5 % par rapport à l'année précédente. Le segment des Soins Ambulatoires de l'entreprise a montré une croissance impressionnante avec un EBITDA Ajusté de 439 millions de dollars, en augmentation de 18,6 %. Sur la base de ces performances solides, Tenet a relevé ses prévisions d'EBITDA Ajusté pour l'exercice 2024 à 3,9-4,0 milliards de dollars, soit une augmentation de 50 millions de dollars. L'entreprise a également démontré une génération robuste de flux de trésorerie avec 2,378 milliards de dollars provenant des activités opérationnelles pour les neuf premiers mois de 2024.
Tenet Healthcare (NYSE: THC) meldete im dritten Quartal 2024 starke Ergebnisse mit einem Nettogewinn von 472 Millionen Dollar (4,89 Dollar pro verwässerter Aktie), einschließlich eines nach Steuern erzielten Gewinns von 209 Millionen Dollar aus Krankenhausverkäufen. Das konsolidierte Adjusted EBITDA erreichte 978 Millionen Dollar, was einem Anstieg von 14,5 % im Jahresvergleich entspricht. Das Segment der Ambulanten Versorgung des Unternehmens zeigte beeindruckendes Wachstum mit einem Adjusted EBITDA von 439 Millionen Dollar, was 18,6 % mehr entspricht. Aufgrund der starken Leistung hob Tenet seine Prognose für das Adjusted EBITDA im Geschäftsjahr 2024 auf 3,9-4,0 Milliarden Dollar an, was einem Anstieg von 50 Millionen Dollar entspricht. Das Unternehmen wies eine robuste Cashflow-Generierung mit 2,378 Milliarden Dollar aus operativen Tätigkeiten in den ersten neun Monaten des Jahres 2024 aus.
- Adjusted EBITDA increased 14.5% to $978 million in Q3 2024
- Ambulatory Care segment Adjusted EBITDA grew 18.6% to $439 million
- Same-hospital admissions increased 5.2% year-over-year
- Operating cash flows improved to $2.378 billion for nine months of 2024
- Net debt to Adjusted EBITDA ratio improved to 2.22x from 3.89x at year-end 2023
- Raised FY 2024 Adjusted EBITDA guidance by $50 million
- Hospital segment revenues declined 3.4% due to facility divestitures
- Emergency Room visits decreased 0.2% year-over-year
- Same-facility surgical cases declined 0.6% on same-business day basis
Insights
Tenet Healthcare delivered an exceptionally strong Q3 2024 with significant financial improvements. Net income surged to
- Adjusted EBITDA grew
14.5% to$978 million - Ambulatory Care segment showed impressive
18.6% EBITDA growth - Strong cash flow with
$2.378 billion from operations - Reduced leverage ratio to 2.22x from 3.89x
The company's strategic divestitures and focus on high-margin ambulatory services are paying off. The raised FY2024 outlook and robust free cash flow generation demonstrate strong operational execution and improving financial health.
The operational metrics reveal strong fundamental performance across both hospital and ambulatory segments. Notable trends include:
- Same-hospital admissions up
5.2% , showing strong patient demand - Ambulatory surgical case revenue per case increased
7.6% - Improved payer mix and higher acuity services driving better margins
The strategic transformation through hospital divestitures while expanding the ambulatory platform positions Tenet for sustained growth. The focus on higher-margin services and operational efficiency is evident in the improving EBITDA margins, particularly in the hospital segment which rose to
-
Net income available to common shareholders in third quarter 2024 was
, or$472 million per diluted share, including an after-tax gain of$4.89 , or$209 million per diluted share, primarily associated with previously announced hospital divestitures$2.16
-
Adjusted diluted earnings per share1 was
in third quarter 2024$2.93
-
Consolidated Adjusted EBITDA1 in third quarter 2024 of
increased$978 million 14.5% over third quarter 2023
-
Third quarter 2024 Ambulatory Care Adjusted EBITDA of
increased$439 million 18.6% over third quarter 2023
-
FY 2024 Adjusted EBITDA Outlook now expected to be in the range of
to$3.9 billion , a$4.0 billion increase$50 million
"Our businesses continue to produce strong results and generate robust free cash flow with same store revenue growth and profitability well above our expectations due to the focused execution of our strategy and disciplined operations," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We have furthered our portfolio transformation and are well-positioned to deliver enhanced value to our patients, physician partners, and shareholders."
Tenet’s results for third quarter 2024 versus third quarter 2023 are as follows:
|
Three Months Ended
|
Nine Months Ended
|
||
($ in millions, except per share results) |
2024 |
2023 |
2024 |
2023 |
Net operating revenues |
|
|
|
|
Net income available to Tenet common shareholders |
|
|
|
|
Net income available to Tenet common shareholders per diluted share |
|
|
|
|
Adjusted EBITDA1 |
|
|
|
|
Adjusted diluted earnings per share1 |
|
|
|
|
-
Net income available to the Company’s common shareholders in the third quarter 2024 was
, or$472 million per diluted share, versus$4.89 , or$101 million per diluted share, in third quarter 2023. Third quarter 2024 results included a pre-tax gain of$0.94 ($348 million after-tax or$209 million per diluted share) primarily associated with the sale of the Company's$2.16 70% majority ownership interest in Brookwood Baptist Health inAlabama .
-
Adjusted EBITDA1 in third quarter 2024 was
compared to$978 million in third quarter 2023, reflecting strong same-hospital admissions growth, strong ambulatory net revenue per case growth, favorable payer mix, and increased Medicaid supplemental revenues in$854 million Michigan , partially offset by higher medical fees as well as the impact of hospital divestitures.
Balance Sheet and Cash Flows
-
Cash flows provided by operating activities for the nine months ended September 30, 2024 were
versus$2.37 8 billion for the nine months ended September 30, 2023.$1.55 0 billion
-
The Company produced free cash flow1 of
for the nine months ended September 30, 2024 versus$1.77 7 billion for the nine months ended September 30, 2023.$1.00 7 billion
-
In the three months ended September 30, 2024, the Company repurchased 795,112 shares of common stock for
. In the nine months ended September 30, 2024, the Company repurchased 5,596,573 shares of common stock for$124 million .$672 million
- The Company’s ratio of net debt to Adjusted EBITDA1 was 2.22x at September 30, 2024 compared to 2.61x at June 30, 2024 and 3.89x at December 31, 2023.
Recent Transaction
-
On October 1, 2024, the Company announced the completion of the sale of its
70% majority ownership interest in Brookwood Baptist Health inBirmingham, Alabama to Orlando Health in the third quarter of 2024. The completed transaction included five hospitals and other related operations. Our outlook for full year 2024 net cash provided by operating activities and free cash flow1 now reflects the anticipated payment of approximately of income taxes, primarily in connection with the net gain on the sale of these facilities.$175 million
Ambulatory Care (Ambulatory) Segment
Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of September 30, 2024, USPI had interests in 520 ambulatory surgery centers (376 consolidated) and 24 surgical hospitals (seven consolidated) in 37 states.
|
Three Months Ended
|
Nine Months Ended
|
||
Ambulatory segment results ($ in millions) |
2024 |
2023 |
2024 |
2023 |
Revenues |
|
|
|
|
Net operating revenues |
|
|
|
|
Same-facility system-wide net patient service revenues2 |
|
|
|
|
Volume Changes versus the Prior-Year Period |
|
|
|
|
Same-facility system-wide surgical cases2 |
1.0 % |
4.1 % |
0.4 % |
6.2 % |
Same-facility system-wide surgical cases on same-business day basis2 |
(0.6) % |
5.8 % |
(0.1) % |
6.8 % |
Adjusted EBITDA, Margins and NCI |
|
|
|
|
Adjusted EBITDA |
|
|
|
|
Adjusted EBITDA margin |
|
|
|
|
Adjusted EBITDA less NCI |
|
|
|
|
-
Third quarter 2024 net operating revenues increased
21.0% compared to third quarter 2023 driven by strong net revenue per case growth, acquisitions of facilities, and increased service lines.
-
Surgical business same-facility system-wide net patient service revenues increased
8.7% in third quarter 2024 compared to third quarter 2023, with cases up1.0% and net revenue per case up7.6% . Net revenue per case growth was driven by higher acuity associated with favorable case mix as well as favorable payer mix.
-
Third quarter 2024 Adjusted EBITDA increased
18.6% compared to third quarter 2023, due to strong net revenue per case growth, disciplined expense management, and contributions from acquisitions and de novo facilities.
Hospital Operations and Services (Hospital) Segment
Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.
|
Three Months Ended
|
Nine Months Ended
|
||
Hospital segment results ($ in millions) |
2024 |
2023 |
2024 |
2023 |
Revenues |
|
|
|
|
Net operating revenues |
|
|
|
|
Same-hospital net patient service revenues3 |
|
|
|
|
Same-Hospital Volume Changes versus the Prior-Year Period |
|
|
|
|
Admissions |
|
|
|
|
Adjusted admissions4 |
|
|
|
|
Outpatient visits (including outpatient ER visits) |
|
(2.0)% |
|
(1.0)% |
Emergency Room visits (inpatient and outpatient) |
(0.2)% |
(0.9)% |
|
|
Hospital surgeries |
|
(0.7)% |
—% |
|
Adjusted EBITDA |
|
|
|
|
Adjusted EBITDA |
|
|
|
|
Adjusted EBITDA margin |
|
|
|
|
-
Third quarter 2024 net operating revenues declined
3.4% from third quarter 2023 primarily due to the impact of hospital divestitures in first quarter 2024, partially offset by strong same hospital admissions growth, favorable payer mix, and improved pricing yield.
-
Same-hospital net patient service revenue per adjusted admission increased
3.3% year-over-year for third quarter 2024 primarily due to improved pricing yield, favorable payer mix, and our focus on growing higher acuity services.
-
Adjusted EBITDA in third quarter 2024 was
compared to$539 million in third quarter 2023, reflecting strong same-hospital admissions growth and revenue per adjusted admission, favorable payer mix, and increased supplemental revenues in$484 million Michigan , partially offset by higher medical fees as well as the impact of hospital divestitures.
2024 Outlook1
Tenet’s Outlook for full year 2024 (consolidated and by segment) and fourth quarter 2024 follows. This outlook reflects the sale of three Coastal South Carolina hospitals on January 31, 2024, the sale of six
CONSOLIDATED ($ in millions, except per share amounts) |
FY 2024 Outlook |
Fourth Quarter
|
Net operating revenues |
|
|
Net income available to Tenet common stockholders |
|
|
Adjusted EBITDA |
|
|
Adjusted EBITDA margin |
|
|
Diluted income per common share |
|
|
Adjusted net income |
|
|
Adjusted diluted earnings per share |
|
|
Equity in earnings of unconsolidated affiliates |
|
|
Depreciation and amortization |
|
|
Interest expense |
|
|
Income tax expense5 |
|
|
Net income available to NCI |
|
|
Weighted average diluted common shares |
~98 million |
~96 million |
NCI cash distributions |
|
|
Net cash provided by operating activities6 |
|
|
Adjusted net cash provided by operating activities6 |
|
|
Capital expenditures |
|
|
Free cash flow6 |
|
|
Adjusted free cash flow6 |
|
|
Ambulatory Segment ($ in millions) |
FY 2024 Outlook |
Net operating revenues |
|
Adjusted EBITDA |
|
NCI |
|
Adjusted EBITDA less NCI |
|
Changes versus prior year7: |
|
Surgical cases volumes |
Up |
Net revenues per surgical case |
Up |
Hospital Segment ($ in millions) |
FY 2024 Outlook |
Net operating revenues |
|
Adjusted EBITDA |
|
NCI |
|
Changes versus prior year7: |
|
Inpatient admissions |
Up |
Adjusted admissions |
Up |
Management’s Webcast Discussion of Results
Tenet management will discuss the Company’s third quarter 2024 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on October 29, 2024. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.
The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on October 29, 2024.
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2023 and other filings with the Securities and Exchange Commission.
Footnotes
-
Tables and discussions throughout this earnings release include certain financial measures, including those related to our fourth quarter and full year 2024 Outlook, that are not in accordance with accounting principles generally accepted in
the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release. - Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.
- For 2024, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2023 through September 30, 2024. Amounts associated with physician practices are excluded.
- Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.
-
Income tax expense is calculated by multiplying
24% (the federal corporate tax rate of21% plus an estimate of state taxes) by the sum of: pretax income less GAAP facility level NCI expense plus permanent differences, and non-deductible interest expense. -
For 2024, Outlook for net cash provided by operating activities, Adjusted net cash provided by operating activities, Free cash flow and Adjusted free cash flow include an estimate of approximately
of net income tax payments associated with the gains on sale of the three hospitals and related operations in$875 million South Carolina , the six hospitals and related operations inCalifornia , and the five hospitals and related operations inAlabama , approximately of which have already been paid as of September 30, 2024.$175 million - Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in
Non-GAAP Financial Measures
The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.
- Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
- Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
- Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
- Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment.
- Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.
- Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.
The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.
The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.
These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.
See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.
Tenet Healthcare Corporation |
|
Financial Statements and Reconciliations |
|
Third Quarter Earnings Release |
|
|
|
Table of Contents |
|
Description |
Page |
Consolidated Statements of Operations |
12 |
Consolidated Balance Sheets |
14 |
Consolidated Statements of Cash Flows |
15 |
Segment Reporting |
17 |
Table #1 – Reconciliations of Net Income to Adjusted Net Income |
18 |
Table #2 – Reconciliations of Net Income to Adjusted EBITDA |
19 |
Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow |
20 |
Table #4 – Reconciliations of Outlook Net Income to Outlook Adjusted Net Income |
21 |
Table #5 – Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA |
22 |
Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow |
23 |
TENET HEALTHCARE CORPORATION |
|||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||||||||
(Unaudited) |
|||||||||||||||||
(Dollars in millions, except per share amounts) |
|
Three Months Ended September 30, |
|||||||||||||||
|
2024 |
|
% |
|
2023 |
|
% |
|
Change |
||||||||
Net operating revenues |
|
$ |
5,122 |
|
|
100.0 |
% |
|
$ |
5,066 |
|
|
100.0 |
% |
|
1.1 |
% |
Grant income |
|
|
4 |
|
|
0.1 |
% |
|
|
3 |
|
|
0.1 |
% |
|
33.3 |
% |
Equity in earnings of unconsolidated affiliates |
|
|
62 |
|
|
1.2 |
% |
|
|
51 |
|
|
1.0 |
% |
|
21.6 |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|||||||
Salaries, wages and benefits |
|
|
2,218 |
|
|
43.3 |
% |
|
|
2,288 |
|
|
45.2 |
% |
|
(3.1 |
)% |
Supplies |
|
|
881 |
|
|
17.2 |
% |
|
|
877 |
|
|
17.3 |
% |
|
0.5 |
% |
Other operating expenses, net |
|
|
1,111 |
|
|
21.6 |
% |
|
|
1,101 |
|
|
21.7 |
% |
|
0.9 |
% |
Depreciation and amortization |
|
|
209 |
|
|
4.1 |
% |
|
|
224 |
|
|
4.5 |
% |
|
|
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
19 |
|
|
0.4 |
% |
|
|
47 |
|
|
0.9 |
% |
|
|
|
Litigation and investigation costs |
|
|
9 |
|
|
0.2 |
% |
|
|
14 |
|
|
0.3 |
% |
|
|
|
Net losses (gains) on sales, consolidation and deconsolidation of facilities |
|
|
(348 |
) |
|
(6.8 |
)% |
|
|
1 |
|
|
— |
% |
|
|
|
Operating income |
|
|
1,089 |
|
|
21.3 |
% |
|
|
568 |
|
|
11.2 |
% |
|
|
|
Interest expense |
|
|
(202 |
) |
|
|
|
|
(227 |
) |
|
|
|
|
|||
Other non-operating income, net |
|
|
35 |
|
|
|
|
|
4 |
|
|
|
|
|
|||
Income before income taxes |
|
|
922 |
|
|
|
|
|
345 |
|
|
|
|
|
|||
Income tax expense |
|
|
(241 |
) |
|
|
|
|
(79 |
) |
|
|
|
|
|||
Net income |
|
|
681 |
|
|
|
|
|
266 |
|
|
|
|
|
|||
Less: Net income available to noncontrolling interests |
|
|
209 |
|
|
|
|
|
165 |
|
|
|
|
|
|||
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
472 |
|
|
|
|
$ |
101 |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||||||
Earnings per share available to Tenet Healthcare Corporation common shareholders: |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
$ |
4.93 |
|
|
|
|
$ |
0.99 |
|
|
|
|
|
|||
Diluted |
|
$ |
4.89 |
|
|
|
|
$ |
0.94 |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||||||
Weighted average shares and dilutive securities outstanding (in thousands): |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
|
95,665 |
|
|
|
|
|
101,544 |
|
|
|
|
|
|||
Diluted |
|
|
96,652 |
|
|
|
|
|
104,425 |
|
|
|
|
|
TENET HEALTHCARE CORPORATION |
|||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||||||||
(Unaudited) |
|||||||||||||||||
(Dollars in millions, except per share amounts) |
|
Nine Months Ended September 30, |
|||||||||||||||
|
2024 |
|
% |
|
2023 |
|
% |
|
Change |
||||||||
Net operating revenues |
|
$ |
15,593 |
|
|
100.0 |
% |
|
$ |
15,169 |
|
|
100.0 |
% |
|
2.8 |
% |
Grant income |
|
|
9 |
|
|
0.1 |
% |
|
|
14 |
|
|
0.1 |
% |
|
(35.7 |
)% |
Equity in earnings of unconsolidated affiliates |
|
|
182 |
|
|
1.2 |
% |
|
|
155 |
|
|
1.0 |
% |
|
17.4 |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|||||||
Salaries, wages and benefits |
|
|
6,707 |
|
|
43.0 |
% |
|
|
6,831 |
|
|
45.0 |
% |
|
(1.8 |
)% |
Supplies |
|
|
2,717 |
|
|
17.4 |
% |
|
|
2,659 |
|
|
17.5 |
% |
|
2.2 |
% |
Other operating expenses, net |
|
|
3,413 |
|
|
22.0 |
% |
|
|
3,319 |
|
|
21.9 |
% |
|
2.8 |
% |
Depreciation and amortization |
|
|
625 |
|
|
4.0 |
% |
|
|
654 |
|
|
4.3 |
% |
|
|
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
75 |
|
|
0.5 |
% |
|
|
84 |
|
|
0.6 |
% |
|
|
|
Litigation and investigation costs |
|
|
18 |
|
|
0.1 |
% |
|
|
28 |
|
|
0.2 |
% |
|
|
|
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
(2,906 |
) |
|
(18.6 |
)% |
|
|
(12 |
) |
|
(0.1 |
)% |
|
|
|
Operating income |
|
|
5,135 |
|
|
32.9 |
% |
|
|
1,775 |
|
|
11.7 |
% |
|
|
|
Interest expense |
|
|
(623 |
) |
|
|
|
|
(674 |
) |
|
|
|
|
|||
Other non-operating income, net |
|
|
89 |
|
|
|
|
|
8 |
|
|
|
|
|
|||
Loss from early extinguishment of debt |
|
|
(8 |
) |
|
|
|
|
(11 |
) |
|
|
|
|
|||
Income before income taxes |
|
|
4,593 |
|
|
|
|
|
1,098 |
|
|
|
|
|
|||
Income tax expense |
|
|
(1,101 |
) |
|
|
|
|
(243 |
) |
|
|
|
|
|||
Net income |
|
|
3,492 |
|
|
|
|
|
855 |
|
|
|
|
|
|||
Less: Net income available to noncontrolling interests |
|
|
610 |
|
|
|
|
|
488 |
|
|
|
|
|
|||
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
2,882 |
|
|
|
|
$ |
367 |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||||||
Earnings per share available to Tenet Healthcare Corporation common shareholders: |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
$ |
29.56 |
|
|
|
|
$ |
3.60 |
|
|
|
|
|
|||
Diluted |
|
$ |
29.27 |
|
|
|
|
$ |
3.41 |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||||||
Weighted average shares and dilutive securities outstanding (in thousands): |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
|
97,505 |
|
|
|
|
|
101,869 |
|
|
|
|
|
|||
Diluted |
|
|
98,518 |
|
|
|
|
|
105,021 |
|
|
|
|
|
TENET HEALTHCARE CORPORATION |
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
(Unaudited) |
||||||||
(Dollars in millions) |
|
September 30, |
|
December 31, |
||||
|
2024 |
|
2023 |
|||||
ASSETS |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
4,094 |
|
|
$ |
1,228 |
|
Accounts receivable |
|
|
2,598 |
|
|
|
2,914 |
|
Inventories of supplies, at cost |
|
|
356 |
|
|
|
411 |
|
Assets held for sale |
|
|
20 |
|
|
|
775 |
|
Other current assets |
|
|
1,691 |
|
|
|
1,839 |
|
Total current assets |
|
|
8,759 |
|
|
|
7,167 |
|
Investments and other assets |
|
|
3,064 |
|
|
|
3,157 |
|
Deferred income taxes |
|
|
36 |
|
|
|
77 |
|
Property and equipment, at cost, less accumulated depreciation and amortization |
|
|
5,552 |
|
|
|
6,236 |
|
Goodwill |
|
|
10,588 |
|
|
|
10,307 |
|
Other intangible assets, at cost, less accumulated amortization |
|
|
1,373 |
|
|
|
1,368 |
|
Total assets |
|
$ |
29,372 |
|
|
$ |
28,312 |
|
|
|
|
|
|
||||
LIABILITIES AND EQUITY |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Current portion of long-term debt |
|
$ |
95 |
|
|
$ |
120 |
|
Accounts payable |
|
|
1,265 |
|
|
|
1,408 |
|
Accrued compensation and benefits |
|
|
879 |
|
|
|
930 |
|
Professional and general liability reserves |
|
|
286 |
|
|
|
254 |
|
Accrued interest payable |
|
|
248 |
|
|
|
200 |
|
Liabilities held for sale |
|
|
12 |
|
|
|
69 |
|
Income tax payable |
|
|
826 |
|
|
|
23 |
|
Other current liabilities |
|
|
1,927 |
|
|
|
1,756 |
|
Total current liabilities |
|
|
5,538 |
|
|
|
4,760 |
|
Long-term debt, net of current portion |
|
|
12,776 |
|
|
|
14,882 |
|
Professional and general liability reserves |
|
|
855 |
|
|
|
792 |
|
Defined benefit plan obligations |
|
|
308 |
|
|
|
335 |
|
Deferred income taxes |
|
|
260 |
|
|
|
326 |
|
Other long-term liabilities |
|
|
1,560 |
|
|
|
1,709 |
|
Total liabilities |
|
|
21,297 |
|
|
|
22,804 |
|
Commitments and contingencies |
|
|
|
|
||||
Redeemable noncontrolling interests in equity of consolidated subsidiaries |
|
|
2,649 |
|
|
|
2,391 |
|
Equity: |
|
|
|
|
||||
Shareholders’ equity: |
|
|
|
|
||||
Common stock |
|
|
8 |
|
|
|
8 |
|
Additional paid-in capital |
|
|
4,849 |
|
|
|
4,834 |
|
Accumulated other comprehensive loss |
|
|
(175 |
) |
|
|
(181 |
) |
Retained earnings (accumulated deficit) |
|
|
2,690 |
|
|
|
(192 |
) |
Common stock in treasury, at cost |
|
|
(3,538 |
) |
|
|
(2,861 |
) |
Total shareholders’ equity |
|
|
3,834 |
|
|
|
1,608 |
|
Noncontrolling interests |
|
|
1,592 |
|
|
|
1,509 |
|
Total equity |
|
|
5,426 |
|
|
|
3,117 |
|
Total liabilities and equity |
|
$ |
29,372 |
|
|
$ |
28,312 |
|
TENET HEALTHCARE CORPORATION |
||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(Unaudited) |
||||||||
(Dollars in millions) |
|
Nine Months Ended |
||||||
|
September 30, |
|||||||
|
2024 |
|
2023 |
|||||
Net income |
|
$ |
3,492 |
|
|
$ |
855 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
625 |
|
|
|
654 |
|
Deferred income tax expense (benefit) |
|
|
(29 |
) |
|
|
75 |
|
Stock-based compensation expense |
|
|
52 |
|
|
|
48 |
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
75 |
|
|
|
84 |
|
Litigation and investigation costs |
|
|
18 |
|
|
|
28 |
|
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
(2,906 |
) |
|
|
(12 |
) |
Loss from early extinguishment of debt |
|
|
8 |
|
|
|
11 |
|
Equity in earnings of unconsolidated affiliates, net of distributions received |
|
|
(9 |
) |
|
|
5 |
|
Amortization of debt discount and debt issuance costs |
|
|
21 |
|
|
|
25 |
|
Net gains from the sale of investments and long-lived assets |
|
|
(2 |
) |
|
|
(25 |
) |
Other items, net |
|
|
(3 |
) |
|
|
(1 |
) |
Changes in cash from operating assets and liabilities: |
|
|
|
|
||||
Accounts receivable |
|
|
183 |
|
|
|
31 |
|
Inventories and other current assets |
|
|
10 |
|
|
|
(49 |
) |
Income taxes |
|
|
821 |
|
|
|
(46 |
) |
Accounts payable, accrued expenses and other current liabilities |
|
|
123 |
|
|
|
(38 |
) |
Other long-term liabilities |
|
|
18 |
|
|
|
10 |
|
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(119 |
) |
|
|
(105 |
) |
Net cash provided by operating activities |
|
|
2,378 |
|
|
|
1,550 |
|
Cash flows from investing activities: |
|
|
|
|
||||
Purchases of property and equipment |
|
|
(601 |
) |
|
|
(543 |
) |
Purchases of businesses or joint venture interests, net of cash acquired |
|
|
(524 |
) |
|
|
(110 |
) |
Proceeds from sales of facilities and other assets |
|
|
4,965 |
|
|
|
38 |
|
Proceeds from sales of marketable securities and long-term investments |
|
|
25 |
|
|
|
40 |
|
Purchases of marketable securities and long-term investments |
|
|
(46 |
) |
|
|
(54 |
) |
Other items, net |
|
|
(18 |
) |
|
|
(7 |
) |
Net cash provided by (used in) investing activities |
|
|
3,801 |
|
|
|
(636 |
) |
Cash flows from financing activities: |
|
|
|
|
||||
Repayments of borrowings |
|
|
(2,212 |
) |
|
|
(1,478 |
) |
Proceeds from borrowings |
|
|
16 |
|
|
|
1,368 |
|
Repurchases of common stock |
|
|
(672 |
) |
|
|
(90 |
) |
Debt issuance costs |
|
|
— |
|
|
|
(16 |
) |
Distributions paid to noncontrolling interests |
|
|
(496 |
) |
|
|
(425 |
) |
Proceeds from the sale of noncontrolling interests |
|
|
13 |
|
|
|
37 |
|
Purchases of noncontrolling interests |
|
|
(127 |
) |
|
|
(127 |
) |
Advances from managed care payers |
|
|
342 |
|
|
|
— |
|
Repayments of advances from managed care payers |
|
|
(160 |
) |
|
|
— |
|
Other items, net |
|
|
(17 |
) |
|
|
13 |
|
Net cash used in financing activities |
|
|
(3,313 |
) |
|
|
(718 |
) |
Net increase in cash and cash equivalents |
|
|
2,866 |
|
|
|
196 |
|
Cash and cash equivalents at beginning of period |
|
|
1,228 |
|
|
|
858 |
|
Cash and cash equivalents at end of period |
|
$ |
4,094 |
|
|
$ |
1,054 |
|
Supplemental disclosures: |
|
|
|
|
||||
Interest paid, net of capitalized interest |
|
$ |
(555 |
) |
|
$ |
(589 |
) |
Income tax payments, net |
|
$ |
(308 |
) |
|
$ |
(212 |
) |
TENET HEALTHCARE CORPORATION |
||||||||||||||||
SEGMENT REPORTING |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
September 30, |
|
September 30, |
||||||||||||
(Dollars in millions) |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net operating revenues: |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
1,139 |
|
|
$ |
941 |
|
|
$ |
3,275 |
|
|
$ |
2,788 |
|
Hospital Operations and Services |
|
|
3,983 |
|
|
|
4,125 |
|
|
|
12,318 |
|
|
|
12,381 |
|
Total |
|
$ |
5,122 |
|
|
$ |
5,066 |
|
|
$ |
15,593 |
|
|
$ |
15,169 |
|
|
|
|
|
|
|
|
|
|
||||||||
Equity in earnings of unconsolidated affiliates: |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
61 |
|
|
$ |
50 |
|
|
$ |
175 |
|
|
$ |
149 |
|
Hospital Operations and Services |
|
|
1 |
|
|
|
1 |
|
|
|
7 |
|
|
|
6 |
|
Total |
|
$ |
62 |
|
|
$ |
51 |
|
|
$ |
182 |
|
|
$ |
155 |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA: |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
439 |
|
|
$ |
370 |
|
|
$ |
1,280 |
|
|
$ |
1,080 |
|
Hospital Operations and Services |
|
|
539 |
|
|
|
484 |
|
|
|
1,667 |
|
|
|
1,449 |
|
Total |
|
$ |
978 |
|
|
$ |
854 |
|
|
$ |
2,947 |
|
|
$ |
2,529 |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA margins: |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
|
38.5 |
% |
|
|
39.3 |
% |
|
|
39.1 |
% |
|
|
38.7 |
% |
Hospital Operations and Services |
|
|
13.5 |
% |
|
|
11.7 |
% |
|
|
13.5 |
% |
|
|
11.7 |
% |
Total |
|
|
19.1 |
% |
|
|
16.9 |
% |
|
|
18.9 |
% |
|
|
16.7 |
% |
|
|
|
|
|
|
|
|
|
||||||||
Capital expenditures: |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
28 |
|
|
$ |
20 |
|
|
$ |
65 |
|
|
$ |
58 |
|
Hospital Operations and Services |
|
|
188 |
|
|
|
156 |
|
|
|
536 |
|
|
|
485 |
|
Total |
|
$ |
216 |
|
|
$ |
176 |
|
|
$ |
601 |
|
|
$ |
543 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
TENET HEALTHCARE CORPORATION |
||||||||||||||||
Additional Supplemental Non-GAAP disclosures |
||||||||||||||||
Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common |
||||||||||||||||
Shareholders to Adjusted Net Income Available to Common Shareholders |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
September 30, |
|
September 30, |
||||||||||||
(Dollars in millions, except per share amounts) |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
472 |
|
|
$ |
101 |
|
|
$ |
2,882 |
|
|
$ |
367 |
|
Less: |
|
|
|
|
|
|
|
|
||||||||
Impairment and restructuring charges, and acquisition-related costs |
|
|
(19 |
) |
|
|
(47 |
) |
|
|
(75 |
) |
|
|
(84 |
) |
Litigation and investigation costs |
|
|
(9 |
) |
|
|
(14 |
) |
|
|
(18 |
) |
|
|
(28 |
) |
Net gains (losses) on sales, consolidation and deconsolidation of facilities |
|
|
348 |
|
|
|
(1 |
) |
|
|
2,906 |
|
|
|
12 |
|
Loss from early extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
|
|
(11 |
) |
Tax and noncontrolling interests impact of above items |
|
|
(130 |
) |
|
|
10 |
|
|
|
(755 |
) |
|
|
17 |
|
Adjusted net income available to common shareholders |
|
$ |
282 |
|
|
$ |
153 |
|
|
$ |
832 |
|
|
$ |
461 |
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings per share |
|
$ |
4.89 |
|
|
$ |
0.94 |
|
|
$ |
29.27 |
|
|
$ |
3.41 |
|
Less: |
|
|
|
|
|
|
|
|
||||||||
Impairment and restructuring charges, and acquisition-related costs |
|
|
(0.20 |
) |
|
|
(0.45 |
) |
|
|
(0.76 |
) |
|
|
(0.80 |
) |
Litigation and investigation costs |
|
|
(0.09 |
) |
|
|
(0.13 |
) |
|
|
(0.19 |
) |
|
|
(0.27 |
) |
Net gains (losses) on sales, consolidation and deconsolidation of facilities |
|
|
3.60 |
|
|
|
(0.01 |
) |
|
|
29.50 |
|
|
|
0.12 |
|
Loss from early extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
(0.08 |
) |
|
|
(0.10 |
) |
Tax and noncontrolling interests impact of above items |
|
|
(1.35 |
) |
|
|
0.09 |
|
|
|
(7.67 |
) |
|
|
0.16 |
|
Adjusted diluted earnings per share |
|
$ |
2.93 |
|
|
$ |
1.44 |
|
|
$ |
8.47 |
|
|
$ |
4.30 |
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average basic shares outstanding (in thousands) |
|
|
95,665 |
|
|
|
101,544 |
|
|
|
97,505 |
|
|
|
101,869 |
|
Weighted average dilutive shares outstanding (in thousands) |
|
|
96,652 |
|
|
|
104,425 |
|
|
|
98,518 |
|
|
|
105,021 |
|
TENET HEALTHCARE CORPORATION |
||||||||||||||||
Additional Supplemental Non-GAAP disclosures |
||||||||||||||||
Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common |
||||||||||||||||
Shareholders to Adjusted EBITDA |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
September 30, |
|
September 30, |
||||||||||||
(Dollars in millions) |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
472 |
|
|
$ |
101 |
|
|
$ |
2,882 |
|
|
$ |
367 |
|
Less: |
|
|
|
|
|
|
|
|
||||||||
Net income available to noncontrolling interests |
|
|
(209 |
) |
|
|
(165 |
) |
|
|
(610 |
) |
|
|
(488 |
) |
Net income |
|
|
681 |
|
|
|
266 |
|
|
|
3,492 |
|
|
|
855 |
|
Income tax expense |
|
|
(241 |
) |
|
|
(79 |
) |
|
|
(1,101 |
) |
|
|
(243 |
) |
Loss from early extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
|
|
(11 |
) |
Other non-operating income, net |
|
|
35 |
|
|
|
4 |
|
|
|
89 |
|
|
|
8 |
|
Interest expense |
|
|
(202 |
) |
|
|
(227 |
) |
|
|
(623 |
) |
|
|
(674 |
) |
Operating income |
|
|
1,089 |
|
|
|
568 |
|
|
|
5,135 |
|
|
|
1,775 |
|
Litigation and investigation costs |
|
|
(9 |
) |
|
|
(14 |
) |
|
|
(18 |
) |
|
|
(28 |
) |
Net gains (losses) on sales, consolidation and deconsolidation of facilities |
|
|
348 |
|
|
|
(1 |
) |
|
|
2,906 |
|
|
|
12 |
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
(19 |
) |
|
|
(47 |
) |
|
|
(75 |
) |
|
|
(84 |
) |
Depreciation and amortization |
|
|
(209 |
) |
|
|
(224 |
) |
|
|
(625 |
) |
|
|
(654 |
) |
Adjusted EBITDA |
|
$ |
978 |
|
|
$ |
854 |
|
|
$ |
2,947 |
|
|
$ |
2,529 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net operating revenues |
|
$ |
5,122 |
|
|
$ |
5,066 |
|
|
$ |
15,593 |
|
|
$ |
15,169 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues |
|
|
9.2 |
% |
|
|
2.0 |
% |
|
|
18.5 |
% |
|
|
2.4 |
% |
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) |
|
|
19.1 |
% |
|
|
16.9 |
% |
|
|
18.9 |
% |
|
|
16.7 |
% |
TENET HEALTHCARE CORPORATION |
||||||||
Additional Supplemental Non-GAAP disclosures |
||||||||
Table #3 – Reconciliations of Net Cash Provided by Operating Activities to |
||||||||
Free Cash Flow and Adjusted Free Cash Flow |
||||||||
(Unaudited) |
||||||||
|
|
2024 |
||||||
(Dollars in millions) |
|
Q3 |
|
YTD |
||||
Net cash provided by operating activities |
|
$ |
1,045 |
|
|
$ |
2,378 |
|
Purchases of property and equipment |
|
|
(216 |
) |
|
|
(601 |
) |
Free cash flow |
|
$ |
829 |
|
|
$ |
1,777 |
|
|
|
|
|
|
||||
Net cash provided by investing activities |
|
$ |
667 |
|
|
$ |
3,801 |
|
Net cash used in financing activities |
|
$ |
(498 |
) |
|
$ |
(3,313 |
) |
|
|
|
|
|
||||
Net cash provided by operating activities |
|
$ |
1,045 |
|
|
$ |
2,378 |
|
Less: |
|
|
|
|
||||
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(55 |
) |
|
|
(119 |
) |
Adjusted net cash provided by operating activities |
|
|
1,100 |
|
|
|
2,497 |
|
Purchases of property and equipment |
|
|
(216 |
) |
|
|
(601 |
) |
Adjusted free cash flow |
|
$ |
884 |
|
|
$ |
1,896 |
|
|
|
2023 |
||||||
(Dollars in millions) |
|
Q3 |
|
YTD |
||||
Net cash provided by operating activities |
|
$ |
503 |
|
|
$ |
1,550 |
|
Purchases of property and equipment |
|
|
(176 |
) |
|
|
(543 |
) |
Free cash flow |
|
$ |
327 |
|
|
$ |
1,007 |
|
|
|
|
|
|
||||
Net cash used in investing activities |
|
$ |
(169 |
) |
|
$ |
(636 |
) |
Net cash used in financing activities |
|
$ |
(214 |
) |
|
$ |
(718 |
) |
|
|
|
|
|
||||
Net cash provided by operating activities |
|
$ |
503 |
|
|
$ |
1,550 |
|
Less: |
|
|
|
|
||||
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(27 |
) |
|
|
(105 |
) |
Adjusted net cash provided by operating activities |
|
|
530 |
|
|
|
1,655 |
|
Purchases of property and equipment |
|
|
(176 |
) |
|
|
(543 |
) |
Adjusted free cash flow |
|
$ |
354 |
|
|
$ |
1,112 |
|
TENET HEALTHCARE CORPORATION |
||||||||||||||||
Additional Supplemental Non-GAAP disclosures |
||||||||||||||||
Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common |
||||||||||||||||
Shareholders to Outlook Adjusted Net Income Available to Common Shareholders |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Fourth Quarter 2024 |
|
FY 2024 |
||||||||||||
(Dollars in millions, except per share amounts) |
|
Low |
|
High |
|
Low |
|
High |
||||||||
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
211 |
|
|
$ |
311 |
|
|
$ |
3,093 |
|
|
$ |
3,193 |
|
Less: |
|
|
|
|
|
|
|
|
||||||||
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1) |
|
|
(57 |
) |
|
|
(7 |
) |
|
|
(150 |
) |
|
|
(100 |
) |
Net gains on sales, consolidation and deconsolidation of facilities(2) |
|
|
— |
|
|
|
— |
|
|
|
2,906 |
|
|
|
2,906 |
|
Loss from early extinguishment of debt(2) |
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
|
|
(8 |
) |
Tax and noncontrolling interests impact of above items |
|
|
10 |
|
|
|
— |
|
|
|
(745 |
) |
|
|
(755 |
) |
Adjusted net income available to common shareholders |
|
$ |
258 |
|
|
$ |
318 |
|
|
$ |
1,090 |
|
|
$ |
1,150 |
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings per share |
|
$ |
2.20 |
|
|
$ |
3.24 |
|
|
$ |
31.56 |
|
|
$ |
32.58 |
|
Less: |
|
|
|
|
|
|
|
|
||||||||
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(0.59 |
) |
|
|
(0.07 |
) |
|
|
(1.53 |
) |
|
|
(1.02 |
) |
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
— |
|
|
|
— |
|
|
|
29.65 |
|
|
|
29.65 |
|
Loss from early extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
(0.08 |
) |
|
|
(0.08 |
) |
Tax and noncontrolling interests impact of above items |
|
|
0.10 |
|
|
|
— |
|
|
|
(7.60 |
) |
|
|
(7.70 |
) |
Adjusted diluted earnings per share |
|
$ |
2.69 |
|
|
$ |
3.31 |
|
|
$ |
11.12 |
|
|
$ |
11.73 |
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average basic shares outstanding (in thousands) |
|
|
95,000 |
|
|
|
95,000 |
|
|
|
97,000 |
|
|
|
97,000 |
|
Weighted average dilutive shares outstanding (in thousands) |
|
|
96,000 |
|
|
|
96,000 |
|
|
|
98,000 |
|
|
|
98,000 |
|
(1) |
The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. |
|
|
(2) |
The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2024. |
TENET HEALTHCARE CORPORATION |
||||||||||||||||
Additional Supplemental Non-GAAP disclosures |
||||||||||||||||
Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation |
||||||||||||||||
Common Shareholders to Outlook Adjusted EBITDA |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Fourth Quarter 2024 |
|
FY 2024 |
||||||||||||
(Dollars in millions) |
|
Low |
|
High |
|
Low |
|
High |
||||||||
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
211 |
|
|
$ |
311 |
|
|
$ |
3,093 |
|
|
$ |
3,193 |
|
Less: |
|
|
|
|
|
|
|
|
||||||||
Net income available to noncontrolling interests |
|
|
(225 |
) |
|
|
(245 |
) |
|
|
(835 |
) |
|
|
(855 |
) |
Income tax expense |
|
|
(84 |
) |
|
|
(114 |
) |
|
|
(1,185 |
) |
|
|
(1,215 |
) |
Interest expense |
|
|
(207 |
) |
|
|
(197 |
) |
|
|
(830 |
) |
|
|
(820 |
) |
Loss from early extinguishment of debt(2) |
|
|
— |
|
|
|
— |
|
|
|
(8 |
) |
|
|
(8 |
) |
Other non-operating income, net |
|
|
26 |
|
|
|
36 |
|
|
|
115 |
|
|
|
125 |
|
Net gains on sales, consolidation and deconsolidation of facilities(2) |
|
|
— |
|
|
|
— |
|
|
|
2,906 |
|
|
|
2,906 |
|
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1) |
|
|
(57 |
) |
|
|
(7 |
) |
|
|
(150 |
) |
|
|
(100 |
) |
Depreciation and amortization |
|
|
(195 |
) |
|
|
(215 |
) |
|
|
(820 |
) |
|
|
(840 |
) |
Adjusted EBITDA |
|
$ |
953 |
|
|
$ |
1,053 |
|
|
$ |
3,900 |
|
|
$ |
4,000 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
211 |
|
|
$ |
311 |
|
|
$ |
3,093 |
|
|
$ |
3,193 |
|
Net operating revenues |
|
$ |
5,007 |
|
|
$ |
5,207 |
|
|
$ |
20,600 |
|
|
$ |
20,800 |
|
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues |
|
|
4.2 |
% |
|
|
6.0 |
% |
|
|
15.0 |
% |
|
|
15.4 |
% |
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) |
|
|
19.0 |
% |
|
|
20.2 |
% |
|
|
18.9 |
% |
|
|
19.2 |
% |
(1) |
The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. |
|
|
(2) |
The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2024. |
TENET HEALTHCARE CORPORATION |
||||||||
Additional Supplemental Non-GAAP disclosures |
||||||||
Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities |
||||||||
to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow |
||||||||
(Unaudited) |
||||||||
|
|
FY 2024 |
||||||
(Dollars in millions) |
|
Low |
|
High |
||||
Net cash provided by operating activities |
|
$ |
1,775 |
|
|
$ |
2,125 |
|
Purchases of property and equipment |
|
|
(800 |
) |
|
|
(900 |
) |
Free cash flow |
|
$ |
975 |
|
|
$ |
1,225 |
|
|
|
|
|
|
||||
Net cash provided by operating activities |
|
$ |
1,775 |
|
|
$ |
2,125 |
|
Less: |
|
|
|
|
||||
Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1) |
|
|
(175 |
) |
|
|
(125 |
) |
Adjusted net cash provided by operating activities |
|
|
1,950 |
|
|
|
2,250 |
|
Purchases of property and equipment |
|
|
(800 |
) |
|
|
(900 |
) |
Adjusted free cash flow(2) |
|
$ |
1,150 |
|
|
$ |
1,350 |
|
(1) |
The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. |
|
|
(2) |
The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029442085/en/
Investor Contact
Will McDowell
469-893-2387
william.mcdowell@tenethealth.com
Media Contact
Robert Dyer
469-893-2640
mediarelations@tenethealth.com
Source: Tenet Healthcare Corporation
FAQ
What was Tenet Healthcare's (THC) Q3 2024 earnings per share?
How much did Tenet's (THC) Adjusted EBITDA grow in Q3 2024?
What is Tenet Healthcare's (THC) updated EBITDA guidance for 2024?